{'fraction_non_alphanumeric': 0.027321703437660338, 'fraction_numerical': 0.008722421754746024, 'mean_word_length': 5.0227887215140985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 9, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cosmetic Photodynamic Therapy

Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s). Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page. Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180  223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w halftone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).


Conditions
All manuscripts are subject to editorial review. Manu scripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Oncology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites
Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983of , 1989of , and 1996of [JAMA 1997277:925-926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Categories of Manuscripts
Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

Clinical Studies and Clinical Translational Research
Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).
Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.
Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a 'positive result' , but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.
Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the develop-ing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.
Editorials are commentaries on current topics or on papers published elsewhere in the issue. Word count limit is 1,500 and 10 references are allowed. They are usually invited by the Editor.
Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in oncology are also welcome. The length should not exceed 500 words.

Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.
Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.
Key words: Please supply 3-10 key words in English that reflect the content of the paper. Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations:
Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180  223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. B/w halftone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800-1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).
The Guidelines for Authors are available at: www.karger.com/ocl_Guidelines

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integ-rity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all selfarchiving, the posted manuscripts must: • Be used for noncommercial purposes only It is the author's responsibility to fulfill these requirements.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf [see Funding Organizations (NIH etc.)].
For self-archiving Author's Choice TM (Gold Open Access) articles, see Author's Choice TM .

Author's Choice TM
Karger's Author's Choice TM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice. The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must: • Follow the terms of the relevant Creative Commons license • Be linked to the final version on www.karger.com • Include the following statement: 'The final, published version of this article is available at http://www.karger.com/?doi= [insert DOI number].' It is the author's responsibility to fulfill these requirements.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice TM , the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders' requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 7 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Disclaimer:
The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Oncology Research and Treatment offers an interdisciplinary forum for cancer research and treatment. Peer-reviewed original and review articles cover a wide range of aspects in medical hematology and oncology, surgical, neurosurgical, gynecological, pediatric and urological oncology, oral and maxillofacial surgery, dermatological oncology, diagnostics, radiation oncology, psychological care, pathology, clinicalexperimental oncology, biometry, and oncological rehabilitation. Continuous medical education and clinical news form a further focus. Compact and current, Oncology Research and Treatment keeps both clinicians and researchers up to date.